The Senate voted 94-1 to pass a bill that would reauthorize the Food and Drug Administration's program to collect fees for product applications, reports Reuters.
The FDA Reauthorization Act would reinstate the agency's user fee program through 2022. The current program, which is set to expire Sept. 30, allows the FDA to collect fees from drug or devicemakers for new product applications. The agency uses these funds — expected to total nearly $9 million by 2022 — to hire more staff and accelerate its product approval processes.
The House unanimously passed the bill last month. It now goes to the president for final approval.
More articles on supply chain:
6 must-reads for supply chain leaders this week
Express Scripts adds 64 drugs to exclusion list
10 most-read supply chain stories in July